[go: up one dir, main page]

BRPI0515319A - análogos de quinolona - Google Patents

análogos de quinolona

Info

Publication number
BRPI0515319A
BRPI0515319A BRPI0515319-0A BRPI0515319A BRPI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A
Authority
BR
Brazil
Prior art keywords
quinolone
analogs
quinolone analogs
present
methods
Prior art date
Application number
BRPI0515319-0A
Other languages
English (en)
Inventor
Jeffrey P Whitten
Fabrice Pierre
Collin Regan
Michael Schwaebe
George Petros Yiannikouros
Michael Jung
Peter Chua
Johnny Y Nagasawa
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/149,007 external-priority patent/US7652134B2/en
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of BRPI0515319A publication Critical patent/BRPI0515319A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

ANáLOGOS DE QUINOLONA. A presente invenção oferece análogos de quinolona que podem inibir a proliferação celular e/ou induzir apoptose celular. A presente invenção também oferece métodos para preparar análogos de quinolona, e métodos de uso dos mesmos.
BRPI0515319-0A 2004-09-17 2005-09-16 análogos de quinolona BRPI0515319A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61103004P 2004-09-17 2004-09-17
US63860304P 2004-12-22 2004-12-22
US68879605P 2005-06-09 2005-06-09
US68898605P 2005-06-09 2005-06-09
US11/149,007 US7652134B2 (en) 2004-09-17 2005-06-09 Methods for converting quinolone esters into quinolone amides
PCT/US2005/033323 WO2006034113A2 (en) 2004-09-17 2005-09-16 Quinolone analogs as cell proliferation inhibitors

Publications (1)

Publication Number Publication Date
BRPI0515319A true BRPI0515319A (pt) 2008-07-22

Family

ID=35735203

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515319-0A BRPI0515319A (pt) 2004-09-17 2005-09-16 análogos de quinolona

Country Status (11)

Country Link
US (1) US7816406B2 (pt)
EP (1) EP1802306A2 (pt)
JP (1) JP2008513485A (pt)
KR (1) KR100989029B1 (pt)
AU (1) AU2005286965B2 (pt)
BR (1) BRPI0515319A (pt)
CA (1) CA2580749C (pt)
IL (1) IL181857A0 (pt)
MX (1) MX2007003282A (pt)
NZ (1) NZ553746A (pt)
WO (1) WO2006034113A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2529046T3 (es) 2005-08-05 2015-02-16 Senhwa Biosciences, Inc. Procedimientos de preparación de análogos de quinolona
US20100305136A1 (en) * 2006-06-08 2010-12-02 Johnny Yasuo Nagasawa Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
WO2007146813A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Pyridinone analogs as cell proliferation inhibitors
DK2061765T3 (en) 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
CN101801190A (zh) * 2007-06-22 2010-08-11 赛林药物股份有限公司 治疗异常细胞增殖性疾病的方法
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
US7910600B2 (en) * 2007-08-31 2011-03-22 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
CA2699382C (en) 2007-09-14 2016-05-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
RU2549895C2 (ru) * 2007-10-05 2015-05-10 Сенхва Байосайенсиз,Инк. Аналоги хинолона и относящиеся к ним способы
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
BR112016026150B1 (pt) 2014-05-09 2019-11-05 Pimera Inc compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
WO2016137471A1 (en) * 2015-02-26 2016-09-01 Nantpharma, Llc Method for enhanced heparin quality
US10857156B2 (en) 2015-11-20 2020-12-08 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
ES2959536T3 (es) * 2015-12-14 2024-02-26 Senhwa Biosciences Inc Formas cristalinas de análogos de quinolona y sus sales
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
CA3057741A1 (en) 2017-03-28 2018-10-04 Pimera, Inc. Novel crystal forms of a pol1 inhibitor
CA3088998A1 (en) 2018-02-15 2019-09-06 Senhwa Biosciences, Inc. Quinolone analogs and their salts, compositions, and method for their use
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
DE3267485D1 (en) 1981-02-18 1986-01-02 Nippon Shinyaku Co Ltd Substituted carboxylic acid derivatives
ZA852802B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzoxazolo-quinoline antibacterial compounds
US4528285A (en) * 1984-04-26 1985-07-09 Abbott Laboratories Methylenedioxy quino-benzothiazine derivatives
ZA852769B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzothiazolo-quinoline antibacterial compounds
WO1989012055A1 (en) * 1988-06-08 1989-12-14 Kyorin Pharmaceutical Co., Ltd. Antitumor agent
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
IE912902A1 (en) 1990-08-24 1992-02-26 Abbott Lab Quinbenzoxazine, quinobenzothiazine, and pyrido-acridine¹antineoplastic agents
JPH04117388A (ja) * 1990-09-07 1992-04-17 Hokuriku Seiyaku Co Ltd チアゾロキノリン―４―カルボン酸誘導体
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6699989B1 (en) 2000-08-28 2004-03-02 B. Vithal Shetty Antiviral and antimicrobial guanidine or biguanidine derivatives
CA2429951A1 (en) * 2000-12-14 2002-06-20 The Procter & Gamble Company Antimicrobial quinolones
US6821969B2 (en) * 2001-02-13 2004-11-23 Pharmacia & Upjohn Company Thioxazinoquinolones as antiviral agents
US6900224B2 (en) 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
BRPI0409105A (pt) 2003-04-07 2006-04-25 Cylene Pharmaceuticals Inc análogos de quinobenzoxazina substituìdos
AU2005222607B2 (en) 2004-03-15 2010-11-25 Sunesis Pharmaceuticals, Inc. SNS-595 and methods of using the same

Also Published As

Publication number Publication date
US7816406B2 (en) 2010-10-19
EP1802306A2 (en) 2007-07-04
KR20070085264A (ko) 2007-08-27
AU2005286965B2 (en) 2009-10-22
MX2007003282A (es) 2007-10-16
JP2008513485A (ja) 2008-05-01
US20060074089A1 (en) 2006-04-06
WO2006034113A2 (en) 2006-03-30
IL181857A0 (en) 2007-07-04
WO2006034113A3 (en) 2006-08-24
KR100989029B1 (ko) 2010-10-25
CA2580749A1 (en) 2006-03-30
CA2580749C (en) 2014-01-28
AU2005286965A1 (en) 2006-03-30
NZ553746A (en) 2010-06-25

Similar Documents

Publication Publication Date Title
BRPI0515319A (pt) análogos de quinolona
NL301145I2 (nl) Tirbanibulin
GB2453058A (en) Kinase antagonists
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CR11731A (es) Composiciones y procedimientos para su preparación y uso
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
IL176142A0 (en) Processes for preparing montelukast sodium
GT200600148A (es) Metodos para el tratamiento y la prevencion de fibrosis
BR112013008140A2 (pt) "compostos imidazotriazinona".
MX391408B (es) Inhibidores de biaril meta-pirimidina de cinasas.
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
ATE497492T1 (de) Reinigung von montelukast
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
ATE528989T1 (de) Kristalline feste rasagilin-base
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
CR9786A (es) Compuestos de bencimidazol-tiofeno
TW200722897A (en) Projection partitioning and aligning
PA8667201A1 (es) Nuevos compuestos farmaceuticos
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
SV2006002232A (es) Inhibidores bace ref. x-16940

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.